About Us

Overview

A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. 

 

The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised financing of $64.5 million (The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest and Casdin Capital).

 

We are currently advancing a pipeline of programs towards the clinic.

A fully integrated discovery, development and manufacturing organization

An experienced management team supported by a renowned Scientific Advisory Board and a Board of Directors with the diverse skills and experience needed to drive success.

Management team

President & CEO

Founder & CSO

Development

Drug Discovery

Board of Directors

President and Chief Executive Officer, A2 Biotherapeutics

Chief Scientific Officer, A2 Biotherapeutics

President, Innovative Targeting Solutions

Managing Partner, The Column Group

Managing Director, Vida Ventures

Founding Partner, Samsara BioCapital

Partner, Nextech Invest

Chief Executive Officer, ADRx

Scientific Advisory Board

Stanford, human immunology & TCRs

Washington U., immunology & neo-antigens

Fred Hutchinson, cancer cell therapy

Harvard, T cell biology

Therapeutic Technology

Regulatory

Investors

Contact

30301 Agoura Road #210, Agoura Hills, CA, 91301

info@a2bio.com

© 2019 A2 Biotherapeutics, Inc.